Utilizing BMP-2 muteins for treatment of multiple myeloma.
Multiple myeloma (MM) represents a haematological cancer characterized by the pathological hyper proliferation of antibody-producing B-lymphocytes. Patients typically suffer from kidney malfunction and skeletal disorders. In the context of MM, the transforming growth factor β (TGFβ) member Activin A...
Main Authors: | Axel Seher, Charlotte Lagler, Thorsten Stühmer, Urs Dietmar Achim Müller-Richter, Alexander Christian Kübler, Walter Sebald, Thomas Dieter Müller, Joachim Nickel |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5425150?pdf=render |
Similar Items
-
The anti-myeloma activity of bone morphogenetic protein 2 predominantly relies on the induction of growth arrest and is apoptosis-independent.
by: Charlotte Lagler, et al.
Published: (2017-01-01) -
Biological activity of a genetically modified BMP-2 variant with inhibitory activity
by: Kübler Alexander C, et al.
Published: (2009-02-01) -
Analyse von BMP2 und BMP2-Derivaten der TGF-β-Familie als potentielles Therapeutikum im Multiplen Myelom
by: Lagler, Charlotte
Published: (2017) -
The Selection of NFκB Inhibitors to Block Inflammation and Induce Sensitisation to FasL-Induced Apoptosis in HNSCC Cell Lines Is Critical for Their Use as a Prospective Cancer Therapy
by: Mario Joachim Johannes Scheurer, et al.
Published: (2019-03-01) -
Receptor oligomerization and beyond: a case study in bone morphogenetic proteins
by: Mueller Thomas D, et al.
Published: (2009-09-01)